



## **Certification of Substances Division**

Certificate of suitability
No. R1-CEP 2005-250-Rev 01

- 1 Name of the substance:
- 2 **ETOMIDATE**
- 3 Name of holder:
- 4 BACHEM S.A.
- 5 Succursale de Vionnaz
- 6 Route du Simplon 22
- 7 Switzerland-1895 Vionnaz
- 8 Site(s) of production:
- 9 SEE ANNEX 1

10

11

19

20 **21** 

26

THIS CERTIFICATE SUPERSEDES THE PREVIOUS CERTIFICATE
R1-CEP 2005-250-REV 00

After examination of the information provided on the manufacturing method and subsequent processes (including purification) or this substance on the site(s) of production listed in annex, we certify that the quality of the substance is suitably controlled by the current version of the monograph **ETOMIDATE** to 1514 of the European Pharmacopoeia, current edition including supplements.

Any unspecified impurity detected by the test for related substances of the monograph is limited to as more than 0.10%.

In the last steps of the synthesis t-butylmethylether and n-heptane are used as solvents. Their residual content is limited by the test for loss on drying described in the monograph, with a limit of t-thore than 0.5%.

The re-test period of the substance is 60 months if stored in an aluminium bottle coated with an epoxy phenolic resin, closed with a polyethylene plug and finally sealed with a polypropylene screw cap.

- The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.
- The submitted dossier must be updated after any significant change that may alter the quality, safety or efficacy of the substance.
- Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice and in accordance with the dossier submitted.

- Failure to comply with these provisions will render this certificate void. 31
- 32 This certificate is renewed from 18 December 2011 according to the provisions
- Resolution AP-CSP (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and 33
- 34 subsequent amendment, and the related guidelines.
- This certificate has one annex of 1 page. 35

Strasbourg, 8 October 2014

- This certificate has: 36
- 37 lines.

On behalf of the Director of/EDQM



DECLARATION OF ACCESS (to be filled in by the certificate I their own responsibility)

> BACHEM S.A., as hold ne certificate of suitability

Rev 01 for Etomidate

hereby authorises ......

name of the pharmaceutical company)

rtificate of sultability in support of their application(s) for the following to use the above-men s): (name of product(s) and marketing number(s), if known)

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature (of the CEP holder):

Address: 7 Allée Kastner, CS 30026 F-67081 Strasbourg (France)

Tel: +33 (0) 3 88 41 30 30 - Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu

Internet: http://www.edgm.eu







## **Certification of Substances Division**

Annex 1: Sites of manufacture for R1-CEP 2005-250-Rev

EDQM Certificate of Suitability CEP No R1-CEP 2005-250-Rev 01